Interestingly, in ovarian cancer, however, the homozygous deletion of ACSL3 is significantly related to the increased risk of recurrence in patients treated with adjuvant chemotherapy, suggesting that ACSL3 may be cancer-specific and possess complicate functions (Jeong et al., 2017). This evidence concerns the gene ACSL3 and ovarian cancer.